Warfarin
Athrombin, Athrombin-k, Coumadin, Panwarfin (warfarin) is a small molecule pharmaceutical. Warfarin was first approved as Athrombin-k on 1982-01-01. It is used to treat atrial fibrillation, postoperative complications, pulmonary embolism, stroke, and thromboembolism amongst others in the USA. The pharmaceutical is active against vitamin K epoxide reductase complex subunit 1.
Download report
Favorite
Searched
Commercial
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Warfarin potassium
Tradename | Company | Number | Date | Products |
---|---|---|---|---|
ATHROMBIN-K | Pharmaceutical Research Associates Inc | N-011771 DISCN | 1982-01-01 | 4 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
coumadin | New Drug Application | 2012-11-15 |
jantoven | ANDA | 2017-08-24 |
warfarin sodium | ANDA | 2023-05-31 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
---|---|---|---|
atrial fibrillation | EFO_0000275 | D001281 | I48.0 |
postoperative complications | — | D011183 | — |
pulmonary embolism | EFO_0003827 | D011655 | I26 |
stroke | EFO_0000712 | D020521 | I63.9 |
thromboembolism | HP_0001907 | D013923 | — |
thrombophlebitis | HP_0004418 | D013924 | — |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
---|---|
G9143 | Warfarin responsiveness testing by genetic technique using any method, any number of specimen(s) |
Level 2: G9143-G9143 | Warfarin Responsiveness Testing |
Clinical
Clinical Trials
399 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Atrial fibrillation | D001281 | EFO_0000275 | I48.0 | — | 22 | 23 | 25 | 47 | 114 |
Healthy volunteers/patients | — | 43 | — | — | 1 | 4 | 48 | ||
Venous thrombosis | D020246 | HP_0004936 | I82.40 | 1 | 5 | 11 | 13 | 15 | 43 |
Pulmonary embolism | D011655 | EFO_0003827 | I26 | — | 2 | 6 | 6 | 14 | 27 |
Stroke | D020521 | EFO_0000712 | I63.9 | 1 | 6 | 17 | 3 | 3 | 26 |
Venous thromboembolism | D054556 | EFO_0004286 | I74 | — | 2 | 5 | 1 | 12 | 20 |
Thromboembolism | D013923 | HP_0001907 | — | 4 | 11 | 3 | 2 | 19 | |
Heart valve diseases | D006349 | EFO_0009551 | I08 | — | 4 | 1 | 2 | 8 | 14 |
Thrombosis | D013927 | — | — | 3 | 3 | 5 | 11 | ||
Hemorrhage | D006470 | MP_0001914 | R58 | — | — | 4 | 3 | 3 | 10 |
Show 28 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Cardiovascular diseases | D002318 | EFO_0000319 | I98 | 1 | — | 5 | — | 4 | 10 |
Myocardial infarction | D009203 | EFO_0000612 | I21 | — | 3 | 2 | — | 3 | 7 |
Atrial flutter | D001282 | EFO_0003911 | — | 1 | 5 | — | — | 5 | |
Heart diseases | D006331 | EFO_0003777 | I51.9 | — | — | 5 | — | — | 5 |
Intracranial thrombosis | D020767 | 1 | 1 | 2 | — | 1 | 4 | ||
Transient ischemic attack | D002546 | EFO_0003764 | G45.9 | — | 1 | 2 | — | — | 3 |
Peripheral vascular diseases | D016491 | EFO_0003875 | I73.9 | — | — | 2 | — | 1 | 3 |
Prostatic neoplasms | D011471 | C61 | 1 | 1 | 1 | — | — | 3 | |
Vascular diseases | D014652 | EFO_0004264 | I77 | — | — | 2 | — | 1 | 3 |
Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | 2 | — | — | 2 |
Show 31 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Embolism and thrombosis | D016769 | — | 1 | — | — | 1 | 2 | ||
Pulmonary hypertension | D006976 | EFO_0001361 | I27.20 | — | 2 | — | — | — | 2 |
Heart valve prosthesis | D006350 | EFO_0003906 | — | 1 | — | — | — | 1 | |
Replacement arthroplasty knee | D019645 | — | 1 | — | — | — | 1 | ||
Hypoprothrombinemias | D007020 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Neoplasms | D009369 | C80 | 8 | — | — | — | 1 | 9 | |
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 6 | — | — | — | — | 6 |
Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 4 | — | — | — | — | 4 |
Pharmacokinetics | D010599 | 3 | — | — | — | 1 | 4 | ||
Alzheimer disease | D000544 | EFO_0000249 | F03 | 3 | — | — | — | — | 3 |
Psoriasis | D011565 | EFO_0000676 | L40 | 2 | — | — | — | — | 2 |
Atopic dermatitis | D003876 | EFO_0000274 | L20 | 2 | — | — | — | — | 2 |
Overactive urinary bladder | D053201 | EFO_1000781 | N32.81 | 2 | — | — | — | — | 2 |
Parkinson disease | D010300 | EFO_0002508 | G20 | 2 | — | — | — | — | 2 |
Ulcerative colitis | D003093 | EFO_0000729 | K51 | 1 | — | — | — | — | 1 |
Show 18 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Oral surgery | D013515 | — | — | — | — | 1 | 1 | ||
Postoperative complications | D011183 | — | — | — | — | 1 | 1 | ||
Oral surgical procedures | D019647 | — | — | — | — | 1 | 1 | ||
Uterine hemorrhage | D014592 | — | — | — | — | 1 | 1 | ||
Periodontal diseases | D010510 | K05.6 | — | — | — | — | 1 | 1 | |
Embolic stroke | D000083262 | — | — | — | — | 1 | 1 | ||
Gastrointestinal hemorrhage | D006471 | K92.2 | — | — | — | — | 1 | 1 | |
Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | — | — | 1 | 1 |
Mesenteric ischemia | D065666 | K55.1 | — | — | — | — | 1 | 1 | |
Bradycardia | D001919 | HP_0001662 | R00.1 | — | — | — | — | 1 | 1 |
Show 8 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | WARFARIN |
INN | warfarin |
Description | 4-hydroxy-3-(3-oxo-1-phenylbutyl)-1-benzopyran-2-one is a member of the class of coumarins that is 4-hydroxycoumarin which is substituted at position 3 by a 1-phenyl-3-oxo-1-butyl group. It is a methyl ketone and a hydroxycoumarin. |
Classification | Small molecule |
Drug class | warfarin analogs |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | CC(=O)CC(c1ccccc1)c1c(O)c2ccccc2oc1=O |
Identifiers
PDB | — |
CAS-ID | 129-06-6 |
RxCUI | — |
ChEMBL ID | CHEMBL1464 |
ChEBI ID | 87732 |
PubChem CID | 54678486 |
DrugBank | DB00682 |
UNII ID | 5Q7ZVV76EI (ChemIDplus, GSRS) |
Target
Agency Approved
VKORC1
VKORC1
Organism
Homo sapiens
Gene name
VKORC1
Gene synonyms
VKOR
NCBI Gene ID
Protein name
vitamin K epoxide reductase complex subunit 1
Protein synonyms
phylloquinone epoxide reductase, vitamin K dependent clotting factors deficiency 2, Vitamin K1 2,3-epoxide reductase subunit 1, vitamin K1 epoxide reductase (warfarin-sensitive)
Uniprot ID
Mouse ortholog
Vkorc1 (27973)
vitamin K epoxide reductase complex subunit 1 (Q9CRC0)
Alternate
No data
Variants
Clinical Variant
Identifier | Target mutation | Effect | Evaluation | Status |
---|---|---|---|---|
VCV000225969 | CYP4F2, 1297G>A, Val433Met | drug response | 2021-03-24 | 1A |
VCV000225947 | NC_000010.11:g.94645745G>A | drug response | 2021-04-12 | 1A |
VCV000002211 | VKORC1, -1639G>A | drug response | 2021-03-24 | 1A |
VCV000226016 | VKORC1, *134G>A | drug response | 2021-03-24 | 1B |
VCV000225975 | VKORC1, 283+837T>C | drug response | 2021-03-24 | 1B |
VCV000037344 | VKORC1, 174-136C>T | drug response | 2021-03-29 | 1B |
VCV000226030 | VKORC1, -1639G>T | drug response | 2018-04-06 | 2A |
VCV000226026 | VKORC1, 283+124G>C | drug response | 2021-03-24 | 2A |
VCV000225983 | VKORC1, 173+324T>G | drug response | 2021-03-24 | 2A |
VCV000017848 | APOE, 526C>T, Arg176Cys | drug response | 2021-03-24 | 2B |
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 62,660 documents
View more details
Safety
Black-box Warning
Black-box warning for: Coumadin, Jantoven, Warfarin sodium
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
43 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more